Syntara on advancing first-in-class Myelofibrosis therapy with multiple pipeline opportunities

Welcome to the latest HotCopper Capital Compass, where we’ve this week spoken to Syntara Ltd (ASX:SNT) chief Gary Phillips for a high-level overview on the biotech company’s objectives in treating blood cancers and fibrosis, what underpins its value proposition, and what lies ahead for CY26.

Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.

Disclaimer: This content has been prepared as part of an ongoing partnership with Syntara Ltd and is intended for informational purposes only.

“We’re a clinical-stage biotech in Sydney, and we’re differentiated from a lot of our peers through three things: We have an in-house development group, we’re global leaders in a field of chemistry, which has led to a unique set of assets, and lastly, we’re owned by smart money,” Mr Phillips told The Market Link.

“We have so much set up that’s giving us so many shots on goal right now,” he added. “This is a great time to be getting a look at the company.”

For a full overview on SNT, you can watch the interview in the browser above.

Join the discussion. See what HotCopper users are saying about Syntara Ltd and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.